(Q40839516)

English

Pretreatment plasma homovanillic acid in schizophrenia and schizoaffective disorder: the influence of demographic variables and the inpatient drug-free period

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Pretreatment plasma homovanillic acid in schizophrenia and schizoaffective disorder: the influence of demographic variables and the inpatient drug-free period (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

0 references

0 references

schizoaffective disorder

1 reference

based on heuristic

inferred from title

author name string

Sharma RP

1

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Javaid JI

2

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Davis JM

3

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Janicak PG

4

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

language of work or name

0 references

publication date

1 September 1998

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Biological Psychiatry

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

44

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

488-492

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900451-4

7 January 2021

Homovanillic acid measurement in clinical research: a review of methodology

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900451-4

7 January 2021

Plasma homovanillic acid and prognosis in Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900451-4

7 January 2021

Dopamine turnover in schizophrenia before and after haloperidol withdrawal. CSF, plasma, and urine studies

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900451-4

7 January 2021

A comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900451-4

7 January 2021

Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900451-4

7 January 2021

Plasma homovanillic acid concentration and the severity of schizophrenic illness

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900451-4

7 January 2021

The effect of neuroleptic discontinuation on psychopathology, involuntary movements, and biochemical measures in patients with persistent tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900451-4

7 January 2021

Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900451-4

7 January 2021

Measurement of 3-methoxy-4-hydroxyphenylacetic acid (HVA) in plasma by high-performance liquid chromatography with electrochemical detector (HPLC-EC)

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900451-4

7 January 2021

Dopaminergic mechanisms and cognitive deficit in schizophrenia. A neurobiological model

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900451-4

7 January 2021

Plasma amine metabolites before and after withdrawal from neuroleptic treatment in chronic schizophrenic inpatients.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900451-4

7 January 2021

A new approach to biochemical evaluation of brain dopamine metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900451-4

7 January 2021

Plasma homovanillic acid levels in first-episode schizophrenia. Psychopathology and treatment response

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900451-4

7 January 2021

Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900451-4

7 January 2021

Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900451-4

7 January 2021

Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900451-4

7 January 2021

Plasma and CSF HVA before and after pharmacological treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900451-4

7 January 2021

Pharmacological effects of methylphenidate on plasma homovanillic acid and growth hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900451-4

7 January 2021

Homovanillic acid in the cerebrospinal fluid: patterns of response after four weeks of neuroleptic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900451-4

7 January 2021

Age of illness onset and schizophrenic symptomatology during an inpatient washout period

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900451-4

7 January 2021

Serum homovanillic acid levels in schizophrenic patients and normal control subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900451-4

7 January 2021

Neuroleptic treatment, symptoms of schizophrenia, and plasma homovanillic acid concentrations revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900451-4

7 January 2021

13. Early intervention with neuroleptics may decrease the l long-term morbidity of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2897%2900451-4

7 January 2021

Identifiers

10.1016/S0006-3223(97)00451-4

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40839516&oldid=1908496756"